Log in to search using one of your social media accounts:


Microglia-derived extracellular vesicles in Alzheimer's Disease: a double-edged sword.

Microglia-derived extracellular vesicles in Alzheimer's Disease: a double-edged sword. Biochem Pharmacol. 2018 Jan 03;: Authors: Trotta T, Panaro MA, Cianciulli A, Mori G, Di Benedetto A, Porro C Abstract Extracellular vesicles (EVs), based on their origin or size, can be classified as apoptotic bodies, microvesicles (MVs)/microparticles (MPs), and exosomes. EVs are one of the new emerging modes of communication between cells that are providing new insights into the pathophysiology of several diseases. EVs released from activated or apoptotic cells contain specific proteins (signaling molecules, receptors, integrins, cytokines), bioactive lipids, nucleic acids (mRNA, miRNA, small non coding RNAs, DNA) from their progenitor cells. In the brain, EVs contribute to intercellular communication through their basal release and uptake by surrounding cells, or release into the cerebrospinal fluid (CSF) and blood. In the central nervous system (CNS), EVs have been suggested as potential carriers in the intercellular delivery of misfolded proteins associated to neurodegenerative disorders, such as tau and amyloid β in Alzheimer's Diseases (AD), α-synuclein in Parkinson's disease (PD), superoxide dismutase (SOD)1 in amyotrophic lateral sclerosis and huntingtin in Huntington's disease. Multiple studies indicate that EVs are involved in the pathogenesis of AD, although their role has not been completely elucidated. The focus of this review is to analyze the...
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Biochem Pharmacol Source Type: research

Related Links:

More News: ALS | Alzheimer's | Brain | Drugs & Pharmacology | Huntington's Disease | Neurology | Parkinson's Disease | Pathology | Study